1. Home
  2. YMAT vs IMRN Comparison

YMAT vs IMRN Comparison

Compare YMAT & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YMAT

J-Star Holding Co. Ltd. Ordinary Shares

HOLD

Current Price

$0.65

Market Cap

9.9M

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.10

Market Cap

9.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YMAT
IMRN
Founded
1970
1994
Country
Taiwan
Australia
Employees
65
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9M
9.6M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
YMAT
IMRN
Price
$0.65
$1.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
11.3M
156.9K
Earning Date
05-13-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.68
52 Week High
$6.45
$2.38

Technical Indicators

Market Signals
Indicator
YMAT
IMRN
Relative Strength Index (RSI) 47.89 49.29
Support Level $0.32 $0.72
Resistance Level $0.87 $1.24
Average True Range (ATR) 0.18 0.11
MACD -0.04 -0.03
Stochastic Oscillator 24.90 23.68

Price Performance

Historical Comparison
YMAT
IMRN

About YMAT J-Star Holding Co. Ltd. Ordinary Shares

J-Star Holding Co Ltd is engaged in the research, development, and manufacturing of carbon fiber for a wide variety-of-products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products. The company has five segments: Bicycle frame, Racket, Crank, Service provision, and Others. The majority of its revenue is generated from the Bicycle frame segment. Geographically, the company operates in Taiwan, China, and other regions.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: